Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) EBITDA (2024 - 2025)

Humacyte has reported EBITDA over the past 2 years, most recently at -$30.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$30.8 million for Q4 2025, down 47.08% from a year ago — trailing twelve months through Dec 2025 was -$46.8 million (up 68.51% YoY), and the annual figure for FY2025 was -$108.1 million, up 27.3%.
  • EBITDA for Q4 2025 was -$30.8 million at Humacyte, down from -$17.5 million in the prior quarter.
  • Over the last five years, EBITDA for HUMA hit a ceiling of $39.1 million in Q1 2025 and a floor of -$56.7 million in Q2 2024.